Summary
Biogen Idec Inc. (now Biogen Inc.) filed an 8-K on October 28, 2013, to announce its third-quarter 2013 financial results. The report primarily directs investors to a press release (Exhibit 99) containing detailed information on the company's operations and financial condition for the period ended September 30, 2013. While the 8-K itself does not contain the detailed financial figures, it serves as a notification and provides access to the official earnings release.
Key Highlights
- 1Biogen Idec announced its third-quarter 2013 financial and operational results on October 28, 2013.
- 2The full details of the financial results are provided in an accompanying press release, furnished as Exhibit 99.
- 3This filing is made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- 4The press release is incorporated by reference into the 8-K filing.
- 5Information furnished under Item 2.02 is not deemed 'filed' for Section 18 of the Exchange Act, limiting liability for its content.
- 6Investors seeking specific financial metrics (revenue, earnings per share, product sales) for Q3 2013 should refer to the press release (Exhibit 99).
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce Biogen Idec's third-quarter 2013 financial results and provide investors with access to the detailed press release containing this information.
You can find the specific financial numbers by referring to Exhibit 99 of this 8-K filing, which is the press release announcing the company's results of operations and financial condition for the three months ended September 30, 2013.
No, the press release furnished under Item 2.02 is generally not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934. This means the company has limited liability regarding the specific content of the press release as if it were formally filed.